Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.

The oncologist - 1 Sept 2016

Santarpia Libero, Bottai Giulia, Kelly Catherine M, Győrffy Balázs, Székely Borbala, Pusztai Lajos

Abstract excerpt

UNLABELLED: : Advances in DNA and RNA sequencing revealed substantially greater genomic complexity in breast cancer than simple models of a few driver mutations would suggest. Only very few, recurrent mutations or copy-number variations in cancer-causing genes have been identified. The two most common alterations in breast cancer are TP53 (affecting the majority of triple-negative breast cancers) and PIK3CA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to DNA Copy Number Variations

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to Molecular Targeted Therapy

Share to Receptor, ErbB-2

Share to Triple Negative Breast Neoplasms

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 27384237
DOI: 10.1634/theoncologist.2015-0369
PMCID: PMC5016060

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.PMID 27384237Read ↗

Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigmsSemantic proximity Read ↗

Therapeutic landscape in mutational triple negative breast cancerSemantic proximity Read ↗

Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing.Semantic proximity Read ↗

Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments.Semantic proximity Read ↗

Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations.Semantic proximity Read ↗

Molecular Pathology of Breast Tumors: Diagnostic and Actionable Genetic Alterations.Semantic proximity Read ↗

Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific TreatmentsSemantic proximity Read ↗

Breast Cancer: Epidemiology, Molecular Classification, Diagnostics and Evolving Treatment Paradigms.Semantic proximity Read ↗

Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.Semantic proximity Read ↗

The Influence of Cancer Molecular Subtypes and Treatment on the Mutation Spectrum in Metastatic Breast Cancers.Semantic proximity Read ↗

Genetic Signature of Breast Cancer Defines Therapeutic Interventions and Indicates Early Drug Resistance.Semantic proximity Read ↗

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.